Cyplasin Announces Financing

    CYPL: OTCBB, Frankfurt Exchange WKN:XYIA

    EDMONTON, Jan. 11 /CNW/ - Cyplasin Biomedical is pleased to announce it
has now completed an equity financing totalling US$1.1 million at US$1.00 per
share. The use of proceeds from this investment will be for the Company's R&D
preclinical studies as well as finalizing the manufacturing of the Cyplasin-SC
    Garth Likes President and CEO of Cyplasin Biomedical stated "we wish to
thank our investors for their continued support of the Company as we meet our
product development goals. Using these funds will see us complete our scale-up
manufacturing of Cyplasin-SC and initiate our toxicology programs which will
allow us to file an Investigational New Drug (IND) application with the FDA in
due course.
    Cyplasin-SC is being developed for use as an anticancer therapeutic drug
for melanoma and skin cancer.

    About Cyplasin-SC(TM)

    Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill
certain types of cancer cells while leaving normal non-cancerous cells
untouched. Cyplasin-SC is a protein originally discovered and isolated by
Professor Petzelt from a marine organism called the sea hare (Aplysia
punctata). The protein can now be manufactured as a recombinant protein which
allows the company to develop the protein as an anti-cancer therapeutic
product. Patents have been issued to the Company covering the Cyplasin-SC

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Canada with a research
laboratory close to Berlin, CBL is dedicated to bringing new anticancer
therapeutics to the marketplace. The Company's current goal is to develop and
commercialize the anticancer properties of Cyplasin-SC(TM) against skin cancer
and melanoma. CBL is publicly traded (CYPL: OTCBB)

    Forward-Looking Statements

    This Press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd., believes that its
expectations and the information in this Press release were based upon
reasonable assumptions at the time when they were made, it can give no
assurance that those expectations will be achieved or that the actual results
will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no
representation or warranty, expressed or implied, as to the accuracy,
reliability or completeness of the information in the Press release, and
neither Cyplasin Biomedical nor any of their directors, officers or employees
will have any liability to you or any other persons resulting from your use of
the information in the Press release. The OTCBB Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news

For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd.,, Tel (780) 469-2975, Fax (780) 699-7933,; Professor Christian Petzelt, Chief Scientific Officer
(CSO), Cyplasin Biomedical Ltd.,, Tel 0049-30-95992761,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890